Relationship between frequency, length, and treatment outcome of exacerbations to baseline lung function and lung density in alpha-1 antitrypsin-deficient COPD

被引:16
作者
Vijayasaratha, Kesavaperumal [1 ]
Stockley, Robert A. [2 ]
机构
[1] Univ Hosp Birmingham NHS Trust, Lung Invest Unit, Birmingham B15 2TH, W Midlands, England
[2] Univ Hosp Birmingham NHS Trust, Birmingham B15 2TH, W Midlands, England
来源
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2012年 / 7卷
关键词
alpha-1 antitrypsin deficiency; antibiotic; exacerbation; gas transfer; lung density; lung function; OBSTRUCTIVE PULMONARY-DISEASE; QUALITY-OF-LIFE; ALPHA(1)-ANTITRYPSIN DEFICIENCY; FLUTICASONE PROPIONATE; INFLAMMATORY MARKERS; AUGMENTATION THERAPY; LONGITUDINAL CHANGES; CT DENSITOMETRY; HEALTH OUTCOMES; NATIONAL HEART;
D O I
10.2147/COPD.S31797
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Diary cards are useful for analyzing exacerbations in chronic obstructive pulmonary disease (COPD), although factors influencing the length and frequency of each episode are poorly understood. This study investigated factors that influence the features of exacerbations in patients with alpha-1 antitrypsin (AAT) deficiency (PiZ phenotype) and COPD. Methods: Daily diary cards were collected over 2 years. Patients had emphysema visualized and quantified by computed tomography scan, and had at least one documented exacerbation in the previous year. Results: The patients (n = 23) had a mean age of 52.5 years, forced expiratory volume in one second (FEV1) of 1.2 L (38.4% predicted), corrected gas transfer (KCO) of 0.90 mmol/min/kPa/L (59.7% predicted), and 15th percentile lung density of 44.55 g/L. Two hundred and sixty-three exacerbations (164 treated) were identified. The frequency of treated exacerbations correlated negatively with KCO% predicted (r = -0.432; P = 0.022). Exacerbation length (determined for 17 of the patients for whom diary card data through the episode were available) correlated negatively with baseline 15th percentile lung density (r = -0.361; P = 0.003), and increased the longer treatment was delayed (r = 0.503; P, 0.001). Treatment delay was shorter with higher day 1 symptom score, lower baseline FEV1, FEV1/forced vital capacity, and lower 15th percentile lung density (r = -0.368, 0.272, 0.461, and 0.786; P = 0.004, 0.036,,0.001, and,0.001, respectively). Time to resolution of exacerbation after treatment initiation was not affected by treatment delay, but correlated negatively with KCO% predicted (r = -0.647; P = 0.007). Conclusion: In alpha-1 antitrypsin deficiency, the frequency and length of resolution of exacerbation were related to baseline gas transfer. Treatment delay adversely affected exacerbation length, and lung density was the best independent predictor of delay in starting treatment. Keywords: alpha-1 antitrypsin deficiency, antibiotic, exacerbation, gas transfer, lung density, lung function
引用
收藏
页码:789 / 796
页数:8
相关论文
共 57 条
[1]  
A Statistics Report from the British Thoracic Society, 2006, BURD LUNG DIS
[2]   Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease - A randomized trial [J].
Aaron, Shawn D. ;
Vandemheen, Katherine L. ;
Fergusson, Dean ;
Maltais, Francois ;
Bourbeau, Jean ;
Goldstein, Roger ;
Balter, Meyer ;
O'Donnell, Denis ;
McIvor, Andrew ;
Sharma, Sat ;
Bishop, Graham ;
Anthony, John ;
Cowie, Robert ;
Field, Stephen ;
Hirsch, Andrew ;
Hernandez, Paul ;
Rivington, Robert ;
Road, Jeremy ;
Hoffstein, Victor ;
Hodder, Richard ;
Marciniuk, Darcy ;
McCormack, David ;
Fox, George ;
Cox, Gerard ;
Prins, Henry B. ;
Ford, Gordon ;
Bleskie, Dominique ;
Doucette, Steve ;
Mayers, Irvin ;
Chapman, Kenneth ;
Zamel, Noe ;
FitzGerald, Mark .
ANNALS OF INTERNAL MEDICINE, 2007, 146 (08) :545-U15
[3]   Mortality after hospitalization for COPD [J].
Almagro, P ;
Calbo, E ;
de Echagüen, AO ;
Barreiro, B ;
Quintana, S ;
Heredia, JL ;
Garau, J .
CHEST, 2002, 121 (05) :1441-1448
[4]   ANTIBIOTIC-THERAPY IN EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY-DISEASE [J].
ANTHONISEN, NR ;
MANFREDA, J ;
WARREN, CPW ;
HERSHFIELD, ES ;
HARDING, GKM ;
NELSON, NA .
ANNALS OF INTERNAL MEDICINE, 1987, 106 (02) :196-204
[5]  
BALL P, 1995, QJM-INT J MED, V88, P61
[6]   Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations [J].
Bhowmik, A ;
Seemungal, TAR ;
Sapsford, RJ ;
Wedzicha, JA .
THORAX, 2000, 55 (02) :114-120
[7]   Reduction of hospital utilization in patients with chronic obstructive pulmonary disease -: A disease-specific self-management intervention [J].
Bourbeau, J ;
Julien, M ;
Maltais, F ;
Rouleau, M ;
Beaupré, A ;
Bégin, R ;
Renzi, P ;
Nault, D ;
Borycki, E ;
Schwartzmann, K ;
Singh, R ;
Collet, JP .
ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (05) :585-591
[8]   Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD [J].
Brusasco, V ;
Hodder, R ;
Miravitlles, M ;
Korducki, L ;
Towse, L ;
Kesten, S .
THORAX, 2003, 58 (05) :399-404
[9]   Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial [J].
Burge, PS ;
Calverley, PMA ;
Jones, PW ;
Spencer, S ;
Anderson, JA ;
Maslen, TK .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 320 (7245) :1297-1303
[10]   A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease [J].
Casaburi, R ;
Mahler, DA ;
Jones, PW ;
Wanner, A ;
San Pedro, G ;
ZuWallack, RL ;
Menjoge, SS ;
Serby, CW ;
Witek, T .
EUROPEAN RESPIRATORY JOURNAL, 2002, 19 (02) :217-224